Month 2 Culture Status and Treatment Duration as Predictors of Recurrence in Pulmonary Tuberculosis: Model Validation and Update

A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis

(2014) Corinne S. Merle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

(2014) Stephen H. Gillespie et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

(2014) Amina Jindani et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse

(2013) Patrick P. J. Phillips et al.   PLoS One

Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model

(2013) Robert S. Wallis et al.   PLoS One

Biomarkers for tuberculosis disease activity, cure, and relapse

(2010) Robert S Wallis et al.   LANCET INFECTIOUS DISEASES

Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis

(2009) Susan E. Dorman et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion

(2009) John L. Johnson et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

(2009) Marcus B Conde et al.   LANCET

Pharmacometrics: A Multidisciplinary Field to Facilitate Critical Thinking in Drug Development and Translational Research Settings

(2008) Jeffrey S. Barrett et al.   JOURNAL OF CLINICAL PHARMACOLOGY